UCBMEX:UCBN 85 Pretax Margin % is 28.89% as of Dec. 2025, which is 50% above its 10-year median of 19.22. GuruFocus rates MEX:UCBN with a GF Score™ of 85/100 and a GF Value™ of MXN1,417.06. The stock has 2 warning signs investors should review. Among 946 Biotechnology companies, UCB ranks better than 88.58% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. UCB's Pre-Tax Income for the
six
months ended in Dec. 2025 was MXN25,912 Mil. UCB's Revenue for the
six
months ended in Dec. 2025 was MXN89,691 Mil. Therefore, UCB's pretax margin for the quarter that ended in Dec. 2025 was 28.89%.
The historical rank and industry rank for UCB's Pretax Margin % or its related term are showing as below:
MEX:UCBN'
s Pretax Margin % Range Over the Past 10 Years
Min: 8.4 Med: 19.22 Max: 23.54
Current: 23.54
MEX:UCBN's Pretax Margin % is ranked better than 88.58% of 946
companies
in the Biotechnology industry
Industry Median: -90.5
vs MEX:UCBN: 23.54
UCB (MEX:UCBN) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
UCB Pretax Margin % Related Terms
UCB Pretax Margin % Historical Data
* Premium members only.
The historical data trend for UCB's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:UCBN vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, UCB's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UCB Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UCB's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where UCB's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCB (MEX:UCBN) has a Pretax Margin % of 28.89% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on UCB and its competitors. This is 50% above median its historical median of 19.22. Over the past decade, UCB's Pretax Margin % has ranged from 8.40 to 23.54. According to the industry distribution chart, UCB ranks #108 out of 946 companies in the Biotechnology industry, placing it in the top 11.4%.
Is UCB's Pretax Margin % too high?
UCB's current Pretax Margin % of 28.89% is 50% above median its 10-year median of 19.22. Over the past 10 years, this metric has ranged from a low of 8.40 to a high of 23.54. Based on the distribution chart, UCB ranks #108 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UCB has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does UCB's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #108 out of 946 companies for Pretax Margin %. This places UCB in the top 11% of its industry — outperforming the majority of peers. Historically, UCB's own Pretax Margin % has ranged from 8.40 to 23.54 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on UCB and its competitors. UCB's current Pretax Margin % is 28.89%, which is 50% above median its own 10-year median of 19.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
UCB (MEX:UCBN) has a current Pretax Margin % of 28.89%. The stock's GF Value™ is MXN1,417.06, compared to a current price of MXN1,692.27 — trading 19.4% above its estimated fair value. The current Pretax Margin % is 28.89%, which is 50% above median its 10-year median of 19.22. UCB's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For UCB (MEX:UCBN), the current Pretax Margin % is 28.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (MEX:UCBN) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be overvalued.
The current stock price of MXN1,692.27 is trading 19.4% above its estimated GF Value™ of MXN1,417.06.
Key valuation signals for MEX:UCBN:
Pretax Margin %: 28.89% (50% above median its 10-year median of 19.22)
GF Value™: MXN1,417.06 vs. price of MXN1,692.27 (19.4% above fair value)
No single metric tells the full story. See the MEX:UCBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
85GF Score
Get the complete analysis for MEX:UCBN
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:UCBN has been successfully added to your 
